A PHASE II TRIAL OF ERLOTINIB AND AT-101 IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR ACTIVATING MUTATIONS.

Trial Profile

A PHASE II TRIAL OF ERLOTINIB AND AT-101 IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS WITH EGFR ACTIVATING MUTATIONS.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs AT 101; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Jun 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 24 May 2010 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 24 May 2010 Actual end date (1 May 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top